+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

P

Actively Recruiting

Substance use problems are common among people who have been in prison. Since many substances remain illegal in Canada, these problems can increase the chance of returning to prison. This research is studying two digital treatments for substance use disorders in individuals recently released from prison to see how well they work and how engaged participants are over six months. The study also looks at rates of relapse and re-incarceration. Participants will be randomly assigned to one of two digital programs. One group will complete a 7-module program based on cognitive behavioural therapy CBT techniques. The other group will complete a 6-module program that combines CBT and mindfulness. Both programs are self-directed and designed to help users manage triggers and avoid substance use. During the study, participants will use their assigned digital treatment over six months. Researchers will assess how feasible and useful each program is, how engaged participants remain, and the effectiveness of the treatments in reducing substance use and re-incarceration. Follow-up evaluations will occur about three months after treatment completion to measure outcomes and gather feedback.

Age: 18Years - 55YearsAll GendersPhase Not Applicable
4 locations
E

Actively Recruiting

Researchers are evaluating three classes of biologic treatments for patients with moderate-to-severe Crohns disease that primarily affects the small bowel ileal-dominant. The study aims to find which biologic class leads to the highest number of patients achieving endoscopic remissionmeaning healed ulcers in the small bowelwithout needing corticosteroids after one year. All treatments used are approved by Health Canada and are studied in a real-world setting. Participants will be randomly assigned to one of three treatment groups at the start of the study a TNF antagonist infliximab or adalimumab, an anti-integrin agent vedolizumab, or an anti-IL23 targeted agent ustekinumab or risankizumab. These treatments are given according to standard care schedules using intravenous or subcutaneous administration at specific weeks and intervals during the study. Participants who are on corticosteroids will begin tapering off these within six weeks of starting their biologic therapy. During the study, participants will undergo evaluations at months 4, 8, and 12, including assessments using the Harvey Bradshaw Index HBI and EuroQOL 5-domain questionnaire EQ-5D, and tests for C-reactive protein and fecal calprotectin levels. At 12 months, a video-recorded ileocolonoscopy will determine if endoscopic remission has been achieved. The study will also monitor clinical remission, treatment persistence, safety, and quality of life over the one-year period.

Age: 18Years +All GendersPhase 4
23 locations
A

Actively Recruiting

Researchers are evaluating new treatments for acute hypoxemic respiratory failure AHRF, a serious lung condition affecting millions worldwide and often leading to death or long-term health issues. This adaptive platform trial tests different interventions across varying severity levels, including non-intubated patients, those on mechanical ventilation, and patients needing extracorporeal life support. The study uses an advanced Bayesian design to efficiently assess multiple therapies and strategies, focusing on improving outcomes for critically ill patients. The trial includes several domains studying various therapies such as ultra-protective ventilation with extracorporeal CO2 removal, different mechanical ventilation strategies, corticosteroid use, and new drug treatments like fludrocortisone and nebulized furosemide. Interventions may involve adjusting ventilator settings, sedation, rehabilitation, or medication dosing over periods ranging from days to weeks. Some domains are observational and collect detailed biomarker and clinical data. The platform allows adding or dropping interventions based on ongoing results, optimizing research efficiency. Participants will undergo regular assessments including physiological and biological measurements, respiratory function tests, and monitoring of clinical outcomes like mortality, ventilator-free days, and organ function scores. Safety and adherence to protocols are closely tracked throughout. The study duration varies by intervention, with some domains enrolling patients over two years and monitoring outcomes up to six months. Participants may experience multiple visits for treatment adjustments, data collection, and follow-up evaluations.

Age: 18Years +All GendersPhase Not Applicable
103 locations
S

Actively Recruiting

Researchers are evaluating the impact of two different default dialysate sodium concentrations on major cardiovascular events and death in adults receiving maintenance haemodialysis for end-stage kidney disease. This pragmatic, cluster-randomised, open-label Phase 4 study compares sodium levels of 137 mmoll and 140 mmoll in real-world dialysis settings across multiple sites globally. Dialysis sites will be randomly assigned to use either a default dialysate sodium concentration of 137 mmoll or 140 mmoll for at least 90% of dialysis sessions. Other aspects of patient care will follow standard local practices. Sites must consent to participate, and individual patients will provide waiver or opt-out consent. The study expects to enroll sites over 5 to 7 years, with each participant followed for approximately 2 to 5 years until the study endpoints are reached. Participants will receive dialysis at their assigned sites with the designated sodium concentration. Researchers will monitor the time to first occurrence of major cardiovascular events or death as the primary outcome. Secondary outcomes include other cardiovascular events and individual components of the composite outcomes. Data collection and patient monitoring will continue throughout the study period, estimated to last around five years per participant.

Age: 18Years +All GendersPhase 4
264 locations
A

Actively Recruiting

Researchers are evaluating multiple treatments for community-acquired pneumonia and other respiratory tract infections in hospitalized patients admitted to intensive care. This adaptive platform trial, called REMAP-CAP, aims to identify the effects of various interventions on patient outcomes, including survival and recovery. It also serves as a flexible research platform to study treatments during respiratory pandemics such as COVID-19, with a specific sub-platform called REMAP-COVID for evaluating COVID-19 treatments in the United States. Participants are randomized to receive one or more interventions from various treatment domains including antibiotics, corticosteroids, antivirals, immune modulators, anticoagulation strategies, and mechanical ventilation approaches. Some interventions have been closed to recruitment while others remain active, and dosing or duration often follows local clinical guidelines or specific protocols. The trial uses an adaptive design that allows modification of treatment assignments based on accumulating data and can study interactions between treatments across domains. During the study, hospitalized patients with respiratory infections will be monitored and assessed for outcomes such as 90-day survival and recovery trajectories, days alive without organ support, and quality of life at six months. Data collected include treatment responses, hospital discharge status, and mortality. The trial is designed to continue enrolling patients adaptively over time, with ongoing evaluation of multiple interventions until conclusive answers about their effects are reached.

Age: 28Days +All GendersPhase 3
408 locations